Utilizing OMICS, RWE, and AI: on the way to personalized medicine

---

Authors

Amélie Zacharie¹ , Marion Mueller²

1. University of Freiburg
2. Novartis

Conference / event

Regulatory Affairs and Drug Development Master submission, May 2024, May 2024 (Virtual)

Poster summary

This poster highlights the utilization of OMICS, RWE, and AI in personalized medicine, showcasing their potential to improve therapeutic response, reduce adverse reactions, and enable proactive interventions, ultimately enhancing patient outcomes and overall quality of life.

Keywords

OMICS, Real-world evidence, Artificial intelligence, Personalized medicine, Precision medicine

Research areas

Pharmacy and Pharmacology

References

1. Bell, J. Predicting disease using genomics. Nature 429, 453–456 (2004). https://doi.org/10.1038/nature02624
2. Agarwala V, Khozin S, Singal G, et al. Real-World Evidence In Support Of Precision Medicine: Clinico Genomic Cancer Data As A Case Study. Health Affairs (Project Hope). 2018 May;37(5):765-772. doi: 10.1377/hlthaff.2017.1579.
3. Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. doi:10.1038/s41591-018-0300-7.

Funding

No data provided

Supplemental files

No data provided

Additional information

Competing interests

Marion Mueller is a full-time employee of Novartis Pharma AG and contributor to IMI ConcePTION, which is a public-private consortium funded by the European Government and the European Federation of Pharmaceutical Industry Associations. Amélie Zacharie has no competing interests.

Data availability statement

Data sharing not applicable to this poster as no datasets were generated or analyzed during the current study.

Creative Commons license

Copyright © 2024 Zacharie et al. This is an open access work distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.